Acupuncture and moxibustion treating lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis
Zhe Chen, Tao Jiang, Yingying Peng, Xiaoyu Qiang, Fengwen Yang, Haiyin Hu, Chunxiang Liu, Myeong Soo Lee
Acupuncture and moxibustion treating lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis
Objective: Lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) affect the quality of life of elderly individuals. Acupuncture and moxibustion are used in the clinic in China for improving LUTS symptoms due to BPH. However, there is no evidence to suggest which is the best option. We compared the efficacy of acupuncture and moxibustion to provide evidence for clinical decision-making.
Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wan Fang Data, and VIP databases were searched from inception to July 2020 to identify the randomized controlled trials (RCTs) of acupuncture and moxibustion for LUTS due to BPH. Two researchers filtered studies and extracted the information independently. This study conducted a network meta-analysis using the Bayesian random method. The interventions ranking was evaluated using the surface under the cumulative ranking curve (SUCRA).
Results: We finally included 40 studies comprising 10 treating therapies and 3655 patients with LUTS caused by BPH. In terms of the International Prostate Symptom Score, maximum urinary flow rate, and quality of life, electroacupuncture (EA) (MD = -3.6, 95% credible interval [CrI] [-5.5, -1.8], very low certainty of evidence; MD = 2.2, 95% CrI [1.1, 3.3], low certainty of evidence; MD = -1.3, 95% CrI [-2.2, -0.43], very low certainty of evidence) may be consistently the optimal treatment compared with other interventions, with SUCRA values of 84%, 81%, and 89%, respectively.
Conclusions: Of all treatments, EA may have the best efficacy with fewer adverse events for LUTS due to BPH. The quality of evidence supporting this result is low to very low certainty of the evidence due to limitations of primary studies; thus, more high-quality RCTs are needed for further evidence.
Acupuncture and moxibustion / Benign prostatic hyperplasia / Lower urinary tract symptoms / Network meta-analysis / Randomized controlled trial
[[1]] |
Roehrborn CG.Pathology of benign prostatic hyperplasia. Int J Impot Res 2008;20(Suppl 3):S11-S18.
|
[[2]] |
Lee SWH, Chan EMC, Lai YK.The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep 2017;7(1):7984.
|
[[3]] |
Egan KB.The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016;43(3):289-297.
|
[[4]] |
Madersbacher S, Sampson N, Culig Z.Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a minireview. Gerontology 2019;65(5):458-464.
|
[[5]] |
Keating GM.Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs 2015;75(2):207-217.
|
[[6]] |
Chughtai B, Forde JC, Thomas DD, et al.Benign prostatic hyperplasia. Nat Rev Dis Primers 2016;2:16031.
|
[[7]] |
Platz EA, Joshu CE, Mondul AM, et al.Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012;188(2):496-501.
|
[[8]] |
Shimizu S, Tsounapi P, Shimizu T, et al.Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction? Int J Urol 2014;21(9):856-864.
|
[[9]] |
Speakman M, Kirby R, Doyle S, et al.Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int 2015;115(4):508-519.
|
[[10]] |
Wang XY, Zong HT, Zhang Y.Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and metaanalysis. Clin Interv Aging 2016;11:1609-1622.
|
[[11]] |
Lloyd GL, Marks JM, Ricke WA.Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation? Curr Urol Rep 2019;20(9):54.
|
[[12]] |
Yoshida M, Flores NM, Vietri J, et al.Burden of benign prostatic hyperplasia among men in Japan: patient-reported outcomes among those diagnosed and experiencing symptoms. Int J Urol 2015;22(10):949-955.
|
[[13]] |
Homma Y, Gotoh M, Kawauchi A, et al.Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017;24(10):716-729.
|
[[14]] |
Kim EH, Larson JA, Andriole GL.Management of benign prostatic hyperplasia. Annu Rev Med 2016;67:137-151.
|
[[15]] |
Roehrborn CG, Manyak MJ, Palacios-Moreno JM, et al.A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 2018;121(4):647-658.
|
[[16]] |
Choo MS, Jeong SJ, Cho SY, et al.Development of decision support formulas for the prediction of bladder outlet obstruction and prostatic surgery in patients with lower urinary tract symptom/ benign prostatic hyperplasia: Part II, external validation and usability testing of a smartphone app. Int Neurourol J 2017;21(Suppl 1):S66-S75.
|
[[17]] |
Welliver C, Essa A.Sexual side effects of medical and surgical benign prostatic hyperplasia treatments. Urol Clin North Am 2016;43(3):393-404.
|
[[18]] |
Thielke S.The risk of suicidality and depression from 5-a reductase inhibitors. JAMA Intern Med 2017;177(5):691-692.
|
[[19]] |
Wei JT, Calhoun E, Jacobsen SJ.Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2008;179(5 Suppl): S75-S80.
|
[[20]] |
Kirby RS, Kirby M, Fitzpatrick JM.Benign prostatic hyperplasia: counting the cost of its management. BJU Int 2010;105(7):901-902.
|
[[21]] |
Gill BC, Ulchaker JC.Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep 2018;19(9):72.
|
[[22]] |
Kim SY, Lee H, Chae Y, et al.A systematic review of costeffectiveness analyses alongside randomised controlled trials of acupuncture. Acupunct Med 2012;30(4):273-285.
|
[[23]] |
Xu J, Deng H, Shen X.Safety of moxibustion: a systematic review of case reports. Evid Based Complement Alternat Med 2014;2014:783704.
|
[[24]] |
Kaptchuk TJ.Acupuncture: theory, efficacy, and practice. Ann Intern Med 2002;136(5):374-383.
|
[[25]] |
Chon TY, Lee MC.Acupuncture. Mayo Clin Proc 2013;88(10):1141-1146.
|
[[26]] |
Lee HY, Yun YJ, Choi JY, et al.Effectiveness and safety of moxibustion for alleviating symptoms of overactive bladder: a prospective, randomized controlled, crossover-design, pilot study. Medicine 2018;97(34):e12016.
|
[[27]] |
Jannini EA, Lenzi A.Sexual dysfunction: is acupuncture a therapeutic option for premature ejaculation? Nat Rev Urol 2011;8(5):235-236.
|
[[28]] |
Zhao Y, Zhou J, Mo Q, et al.Acupuncture for adults with overactive bladder: a systematic review and meta-analysis of randomized controlled trials. Medicine 2018;97(8):e9838.
|
[[29]] |
Zhang W, Ma L, Bauer BA, et al.Acupuncture for benign prostatic hyperplasia: a systematic review and meta-analysis. PloS one 2017;12(4):e0174586.
|
[[30]] |
Hutton B, Salanti G, Caldwell DM, et al.The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162(11):777-784.
|
[[31]] |
Shamseer L, Moher D, Clarke M, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
|
[[32]] |
Higgins JP, Altman DG, Gøtzsche PC, et al.The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
|
[[33]] |
Chen YW, Du YH, Xiong J, et al.Acupuncture and moxibustion versus western medicine for benign prostatic hyperplasia: a systematic review. Chin J Trad Chin Med Pharm 2010;25(6):902-906.
|
[[34]] |
Takakura N, Takayama M, Nasu M, et al.Patient blinding with blunt tip placebo acupuncture needles: comparison between 1mm and 2mm skin press. J Integr Med 2018;16(3):164-171.
|
/
〈 | 〉 |